SXTP Stock Forecast & Price Target

60 Degrees is supported by a credible multi-pronged growth strategy centered on ARAKODA commercialization and pipeline expansion into higher-value infectious disease markets. The February GoodRx launch and April Runway Health partnership broaden access to ARAKODA, while March data showing all three enrolled babesiosis patients were cured after tafenoquine treatment strengthens the clinical case for expansion into relapsing babesiosis. The Australian Chestnut extract opportunity adds a non-Rx revenue path, and despite dilution from recent ATM sales, the valuation still implies 170% upside with key risks tied to regulatory approval and future capital raises.

60 Degrees is under pressure from weak commercial execution, as Q1 FY26 product revenue fell to $162,000 versus a $300,000-$400,000 2H25 run-rate, with unit sales down 19% year-over-year to 1,276 boxes and no forward guidance to signal a rebound. The company also posted a $2.2 million net loss on just $0.2 million of sales, while operating expenses rose to $2.2 million and cash ended at $3.3 million after roughly $3.4 million of ATM proceeds, underscoring a dependence on ongoing equity financing amid an annual burn rate of about $8 million. Beyond the near-term revenue miss, the lack of visibility on ARAKODA, tafenoquine, and babesiosis development heightens risk that clinical programs will require dilutive funding or partnering, leaving the stock vulnerable to further downside.